Skip to main content
    I

    IGC Pharma, Inc. (IGC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $0.19
    +0.00 (+0.11%)

    Market Cap: $20.54M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    IGC Pharma, Inc. (IGC) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect IGC Pharma (IGC) to earn -$0.09 per share in the fiscal year ending Mar 31, 2027, on revenue of $1.00M. Over the last 30 days, 0 estimates for the fiscal year ending Mar 31, 2027 were revised up and 1 down. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$0.08.

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    Fiscal year ending Mar 31, 2027
    -$0.09
    EPS consensus, revenue $1.00M
    Fiscal year ending Dec 31, 2027
    -$0.08
    EPS consensus, revenue $958000

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Mar 31, 2027-$0.09-$0.09 to -$0.091$1.00M$1.00M to $1.00M1
    Dec 31, 2027-$0.08-$0.08 to -$0.081$958000$958000 to $9580001

    Quarterly Estimates

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.02-$0.02 to -$0.021$280000$280000 to $2800001

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 0 upward and 1 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Mar 31, 202701
    Fiscal year ending Dec 31, 202700
    Quarter ending Dec 31, 202600

    EPS Trend

    The EPS consensus for the fiscal year ending Mar 31, 2027 has held over the last 90 days.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Mar 31, 2027-$0.09-$0.09-$0.09-$0.09-$0.09N/A
    Fiscal year ending Dec 31, 2027-$0.08-$0.09-$0.09-$0.09-$0.09N/A
    Quarter ending Dec 31, 2026-$0.02-$0.02-$0.03-$0.03-$0.03N/A

    Frequently Asked Questions About IGC

    What is the IGC stock forecast?

    Consensus analyst estimates put IGC Pharma's EPS at -$0.09 for the fiscal year ending Mar 31, 2027, on revenue of $1.00M.

    What EPS do analysts expect from IGC next year?

    For the fiscal year ending Mar 31, 2027, the consensus EPS estimate is -$0.09, with estimates from -$0.09 to -$0.09 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.08, with estimates from -$0.08 to -$0.08 from 1 analyst.

    What revenue do analysts expect from IGC Pharma next year?

    For the fiscal year ending Mar 31, 2027, the consensus revenue estimate is $1.00M, with estimates from $1.00M to $1.00M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $958000, with estimates from $958000 to $958000.

    How many analysts cover IGC?

    1 analyst estimates EPS for IGC Pharma for the fiscal year ending Mar 31, 2027.